Translations:Anti-obesity medication/21/en
| Medication Name | Trade name(s) | Mechanism of action | Current FDA Status | placebo-adjusted percent bodyweight lost (highest dose studied) |
|---|---|---|---|---|
| Retatrutide | GLP-1, GIP, and glucagon receptor triple agonist | In clinical trials | 24 percent in a Phase II trial | |
| Exenatide | Byetta | GLP-1 receptor agonist | Approved for type 2 diabetes | 2.5 kilograms (5.5 lb) |
| Cetilistat | Absorption inhibitor | Not approved | 1.5 kilograms (3.3 lb) | |
| Tesofensine (NS2330) | Serotonin–norepinephrine–dopamine reuptake inhibitor | Not FDA approved | 10.6 percent |